Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Rapid Acting Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global rapid acting insulin market reached a value of US$ XX Billion in 2021. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Rapid acting insulin is a medication used to control glucose levels in patients with diabetes. It is either inhaled or administered into the bloodstream with a syringe, a pre-filled pen, or an insulin pump. It is taken prior to meals and snacks to bring overly high blood glucose to a normal level and surge the level of bolus insulin. At present, new insulin formulations like novel ultra-paid-acting insulins that enhance absorption are considered a suitable option for people who cannot achieve postprandial glycemic targets with other bolus insulins.

Rapid Acting Insulin Market Trends:

Diabetes mellitus (DM) and poorly controlled blood glucose can increase the risk of mortality and severity among patients with coronavirus disease (COVID-19). This represents one of the key factors fueling the need for rapid acting insulins to monitor blood glucose levels. Apart from this, the growing prevalence of type 1 diabetes on account of exposure to viruses and other environmental factors and low levels of vitamin D acts as another factor propelling the demand for rapid acting insulins across the globe. This can also be attributed to the increasing instances of neonatal jaundice in newborns, in confluence with improving diagnostic modalities. In addition to this, as the risk of developing diabetes increases with age, the rising global geriatric population is facilitating the market growth. Furthermore, leading market players are introducing ready-to-use rapid acting insulin kits that are fast, accessible in vials and a pen presentation, and help enhance glycemic control in both adults and children. These players are also focusing on mergers and acquisitions (M&A), which is anticipated to contribute to the development of new-generation product variants.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global rapid acting insulin market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

  • Lispro Insulin
  • Aspart Insulin
  • Glulisine Insulin
     

Breakup by Indication:

  • Type 1 Diabetes
  • Type 2 Diabetes
     

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Stores
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
    Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Product, Indication, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the global rapid acting insulin market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global rapid acting insulin market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global rapid acting insulin market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Rapid Acting Insulin Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Product
    6.1    Lispro Insulin
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Aspart Insulin
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Glulisine Insulin
        6.3.1 Market Trends
        6.3.2 Market Forecast
7    Market Breakup by Indication
    7.1    Type 1 Diabetes
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Type 2 Diabetes
        7.2.1 Market Trends
        7.2.2 Market Forecast
8    Market Breakup by Distribution Channel
    8.1    Hospital Pharmacies
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Drug Stores and Retail Pharmacies
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Online Stores
        8.3.1 Market Trends
        8.3.2 Market Forecast
9    Market Breakup by Region
    9.1    North America
        9.1.1 United States
           9.1.1.1 Market Trends
           9.1.1.2 Market Forecast
        9.1.2 Canada
           9.1.2.1 Market Trends
           9.1.2.2 Market Forecast
    9.2    Asia-Pacific
        9.2.1 China
           9.2.1.1 Market Trends
           9.2.1.2 Market Forecast
        9.2.2 Japan
           9.2.2.1 Market Trends
           9.2.2.2 Market Forecast
        9.2.3 India
           9.2.3.1 Market Trends
           9.2.3.2 Market Forecast
        9.2.4 South Korea
           9.2.4.1 Market Trends
           9.2.4.2 Market Forecast
        9.2.5 Australia
           9.2.5.1 Market Trends
           9.2.5.2 Market Forecast
        9.2.6 Indonesia
           9.2.6.1 Market Trends
           9.2.6.2 Market Forecast
        9.2.7 Others
           9.2.7.1 Market Trends
           9.2.7.2 Market Forecast
    9.3    Europe
        9.3.1 Germany
           9.3.1.1 Market Trends
           9.3.1.2 Market Forecast
        9.3.2 France
           9.3.2.1 Market Trends
           9.3.2.2 Market Forecast
        9.3.3 United Kingdom
           9.3.3.1 Market Trends
           9.3.3.2 Market Forecast
        9.3.4 Italy
           9.3.4.1 Market Trends
           9.3.4.2 Market Forecast
        9.3.5 Spain
           9.3.5.1 Market Trends
           9.3.5.2 Market Forecast
        9.3.6 Russia
           9.3.6.1 Market Trends
           9.3.6.2 Market Forecast
        9.3.7 Others
           9.3.7.1 Market Trends
           9.3.7.2 Market Forecast
    9.4    Latin America
        9.4.1 Brazil
           9.4.1.1 Market Trends
           9.4.1.2 Market Forecast
        9.4.2 Mexico
           9.4.2.1 Market Trends
           9.4.2.2 Market Forecast
        9.4.3 Others
           9.4.3.1 Market Trends
           9.4.3.2 Market Forecast
    9.5    Middle East and Africa
        9.5.1 Market Trends
        9.5.2 Market Breakup by Country
        9.5.3 Market Forecast
10    SWOT Analysis
    10.1    Overview
    10.2    Strengths
    10.3    Weaknesses
    10.4    Opportunities
    10.5    Threats
11    Value Chain Analysis
12    Porters Five Forces Analysis

    12.1    Overview
    12.2    Bargaining Power of Buyers
    12.3    Bargaining Power of Suppliers
    12.4    Degree of Competition
    12.5    Threat of New Entrants
    12.6    Threat of Substitutes
13    Price Analysis
14    Competitive Landscape

    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    Adocia
           14.3.1.1 Company Overview
           14.3.1.2 Product Portfolio
           14.3.1.3 Financials
        14.3.2    Biocon Limited
           14.3.2.1 Company Overview
           14.3.2.2 Product Portfolio
           14.3.2.3 Financials
           14.3.2.4 SWOT Analysis
        14.3.3    Eli Lilly and Company
           14.3.3.1 Company Overview
           14.3.3.2 Product Portfolio
           14.3.3.3 Financials
           14.3.3.4 SWOT Analysis
        14.3.4    Gan & Lee Pharmaceuticals Co. Ltd.
           14.3.4.1 Company Overview
           14.3.4.2 Product Portfolio
           14.3.4.3 Financials
        14.3.5    Geropharm
           14.3.5.1 Company Overview
           14.3.5.2 Product Portfolio
        14.3.6    MannKind Corporation
           14.3.6.1 Company Overview
           14.3.6.2 Product Portfolio
           14.3.6.3 Financials
           14.3.6.4 SWOT Analysis
        14.3.7    Merck & Co. Inc. 
           14.3.7.1 Company Overview
           14.3.7.2 Product Portfolio
           14.3.7.3 Financials
           14.3.7.4 SWOT Analysis
        14.3.8    Novo Nordisk A/S
           14.3.8.1 Company Overview
           14.3.8.2 Product Portfolio
           14.3.8.3 Financials
           14.3.8.4 SWOT Analysis
        14.3.9    Sanofi S.A.
           14.3.9.1 Company Overview
           14.3.9.2 Product Portfolio
           14.3.9.3 Financials
           14.3.9.4 SWOT Analysis
        14.3.10    Wockhardt Ltd.
           14.3.10.1 Company Overview
           14.3.10.2 Product Portfolio
           14.3.10.3 Financials

List of Figures

Figure 1: Global: Rapid Acting Insulin Market: Major Drivers and Challenges
Figure 2: Global: Rapid Acting Insulin Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Rapid Acting Insulin Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Rapid Acting Insulin Market: Breakup by Product (in %), 2021
Figure 5: Global: Rapid Acting Insulin Market: Breakup by Indication (in %), 2021
Figure 6: Global: Rapid Acting Insulin Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Rapid Acting Insulin Market: Breakup by Region (in %), 2021
Figure 8: Global: Rapid Acting Insulin (Lispro Insulin) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Rapid Acting Insulin (Lispro Insulin) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Rapid Acting Insulin (Aspart Insulin) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Rapid Acting Insulin (Aspart Insulin) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Rapid Acting Insulin (Glulisine Insulin) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Rapid Acting Insulin (Glulisine Insulin) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Rapid Acting Insulin (Type 1 Diabetes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Rapid Acting Insulin (Type 1 Diabetes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Rapid Acting Insulin (Type 2 Diabetes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Rapid Acting Insulin (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Rapid Acting Insulin (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Rapid Acting Insulin (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Rapid Acting Insulin (Online Stores) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Rapid Acting Insulin (Online Stores) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: North America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: North America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: United States: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: United States: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Canada: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Canada: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Asia-Pacific: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Asia-Pacific: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: China: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: China: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: Japan: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: Japan: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: India: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: India: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: South Korea: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: South Korea: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: Australia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: Australia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Indonesia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Indonesia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: Europe: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Europe: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Germany: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Germany: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: France: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: France: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: United Kingdom: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: United Kingdom: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Italy: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Italy: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Spain: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Spain: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Russia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Russia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Latin America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Latin America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Brazil: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Brazil: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Mexico: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Mexico: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Middle East and Africa: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Middle East and Africa: Rapid Acting Insulin Market: Breakup by Country (in %), 2021
Figure 72: Middle East and Africa: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Global: Rapid Acting Insulin Industry: SWOT Analysis
Figure 74: Global: Rapid Acting Insulin Industry: Value Chain Analysis
Figure 75: Global: Rapid Acting Insulin Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Rapid Acting Insulin Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Rapid Acting Insulin Market Forecast: Breakup by Product (in Million US$), 2022-2027
Table 3: Global: Rapid Acting Insulin Market Forecast: Breakup by Indication (in Million US$), 2022-2027
Table 4: Global: Rapid Acting Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 5: Global: Rapid Acting Insulin Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 6: Global: Rapid Acting Insulin Market: Competitive Structure
Table 7: Global: Rapid Acting Insulin Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links